News | July 27, 2025
Laurus Labs to invest €5 million in JV KRKA Pharma
The purpose of this investment is to meet the expenditure relating to the civil works to be undertaken for setting up of a manufacturing facility
The purpose of this investment is to meet the expenditure relating to the civil works to be undertaken for setting up of a manufacturing facility
The registered capital of the newly founded company is € 50 million
KRKA holds 51% and Laurus Labs holds 49% shareholding
Subscribe To Our Newsletter & Stay Updated
